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Iron is essential for life, but excess iron can be toxic. As a potent free radical creator,
iron generates hydroxyl radicals leading to significant oxidative stress. Since iron is
not excreted from the body, it accumulates with age in tissues, including the retina,
predisposing to age-related oxidative insult. Both hereditary and acquired retinal diseases
are associated with increased iron levels. For example, retinal degenerations have been
found in hereditary iron overload disorders, like aceruloplasminemia, Friedreich’s ataxia,
and pantothenate kinase-associated neurodegeneration. Similarly, mice with targeted
mutation of the iron exporter ceruloplasmin and its homolog hephaestin showed
age-related retinal iron accumulation and retinal degeneration with features resembling
human age-related macular degeneration (AMD). Post mortem AMD eyes have increased
levels of iron in retina compared to age-matched healthy donors. Iron accumulation in
AMD is likely to result, in part, from inflammation, hypoxia, and oxidative stress, all of
which can cause iron dysregulation. Fortunately, it has been demonstrated by in vitro and
in vivo studies that iron in the retinal pigment epithelium (RPE) and retina is chelatable. Iron
chelation protects photoreceptors and retinal pigment epithelial cells (RPE) in a variety
of mouse models. This has therapeutic potential for diminishing iron-induced oxidative
damage to prevent or treat AMD.
Keywords: iron, retina, age-related macular degeneration (AMD), chelator, oxidative stress, ferroportin,
ceruloplasmin, hephaestin
INTRODUCTION
As an important part of many metabolic processes, iron is essen-
tial for life. However, excess iron can be toxic to tissues. Iron
is a crucial component of enzymes of the citric acid cycle and
electron transport chain, making iron essential for adenosine
triphosphate (ATP) production (Wigglesworth and Baum, 1988;
Poss and Tonegawa, 1997). Iron is also required by ribonucleoside
reductase which is the rate-limiting enzyme of the first metabolic
reaction in DNA synthesis (Wigglesworth and Baum, 1988). In
the central nervous system (CNS), oligodendrocytes require iron
formyelin synthesis andmaintenance (LeVine andMacklin, 1990;
Morris et al., 1992). Iron is an essential cofactor for synthesis
of neurotransmitters, including dopamine, norepinephrine, and
serotonin (Youdim, 1990). Thus, disruption of iron homeosta-
sis may be involved in diseases of the CNS. Iron deficiency in
children can cause auditory defects due to myelin disruption
(Roncagliolo et al., 1998). Demyelinating diseases like multiple
sclerosis are associated with cellular iron homeostasis dysfunction
(Drayer et al., 1987).
In retina, iron is particularly critical for the visual pho-
totransduction cascade. RPE65, an iron containing protein, is
dependent on iron for isomerohydrolase activity. In the retinal
pigment epithelium (RPE), this activity is important in catalyz-
ing the conversion of all-trans-retinyl ester to 11-cis-retinol in
the visual cycle (Moiseyev et al., 2005). 11-cis-retinol leads to 11-
cis-retinaldehyde, the photosensitive component of rhodopsin.
Photoreceptor cells continuously shed and synthesize their disc
membranes, depending on iron-containing enzymes like fatty
acid desaturase for biogenesis of lipids which is used in disc
membrane replacement (Shichi, 1969). Although iron is essen-
tial for retinal function, excessive iron can be toxic. Ferrous iron
can catalyze the conversion of hydrogen peroxide to hydroxyl rad-
ical, which is the most damaging of the reactive oxygen species.
Oxidative damage caused by hydroxyl radical includes lipid per-
oxidation, DNA strand breakage and biomolecule degradation
(Halliwell and Gutteridge, 1984). Hydroxyl radicals have been
implicated in the pathogenesis of Alzheimer’s and other CNS dis-
eases (Smith et al., 1997). Since the main function of the RPE cells
is phagocytize lipid-rich, easily oxidized photoreceptor outer seg-
ments in a high oxygen tension environment, the retina and RPE
are particularly prone to oxidative damage. Therefore, iron must
be carefully regulated in the eye to provide necessary iron without
giving rise to oxidative damage. Retinal iron deficiency has not
been found to be a clinical problem, perhaps because the retina is
very efficient at taking up whatever iron is available in the circu-
lation, and/or because retinal iron stores significantly exceed iron
needs.
GENERAL IRON HOMEOSTASIS
In the circulation, iron exists in two forms: heme and non-heme
iron. The majority of non-heme iron is bound to transferrin
(Baker and Morgan, 1994), which is capable of binding two
molecules of ferric iron. Adults have approximately 3mg of circu-
lating non-heme iron, only saturating 30% of transferrin binding
sites. However, transferrin cannot cross the tight junctions of the
blood brain barrier (BBB); therefore, cells that comprise the BBB
must import iron and transfer it into neural tissue. Iron-laden
transferrin binds to transferrin receptor (TfR) on the cell surface,
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and this complex is internalized into endosomes. In low pH, iron
is released (Sipe and Murphy, 1991) and exported by endosomes
for use, storage in ferritin, a multisubunit protein consisting of
H- and L-chains (Aisen et al., 2001) or export. Upon iron delivery,
transferrin is recycled to the surface (Hunt and Davis, 1992).
Ferroportin exports ferrous iron that is not utilized or stored
in the cell (Abboud and Haile, 2000; Donovan et al., 2000; McKie
et al., 2000), but exported iron must be oxidized to be accepted by
transferrin in the circulation. Oxidation of iron is accomplished
by the ferroxidases such as, ceruloplasmin (Osaki et al., 1966),
hephaestin (Heph) (Vulpe et al., 1999), amyloid precursor protein
(APP) (Duce et al., 2010) or zyklopen (Chen et al., 2010). These
enzymes are crucial for iron export and when disrupted result
in cellular iron accumulation and degeneration. Ceruloplasmin,
a copper binding protein, contains over 95% of copper found
in plasma. Mutation of a copper transporter in Wilson’s disease
causes decreased serum ceruloplasmin levels resulting from fail-
ure of copper incorporation into ceruloplasmin. Hephaestin is
50% identical to ceruloplasmin at the amino acid level. In the sex-
linked anemia mouse, heph has been identified as the disrupted
gene product. In these mice, failure of hephaestin to export iron
from the enterocyte into the circulation results in low serum iron
and enterocyte iron increase (Vulpe et al., 1999). Unlike ceru-
loplasmin, which is a secreted plasma protein or glycosylphos-
phatidylinositol (GPI) membrane-anchored protein (Patel and
David, 1997), Heph is present only as a membrane-bound pro-
tein. APP, a type I transmembrane protein precursor, was found
to be a functional ferroxidase. Both full-length and soluble APP
species can interact with ferroportin to facilitate iron export from
neurons and other cells (Duce et al., 2010). In Alzheimer’s disease,
iron export by APP is inhibited by elevated extracullular Zn2+
dissociating from β-Amyloid. The APP domain responsible for
ferroxidase activity has been debated (Ebrahimi et al., 2012). In
2010, zyklopen was identified as another multicopper ferroxidase
and plays a role in placental iron transport. Immunostaining of
zyklopen identified its expression in the brain, kidney, testes and
retina but not in the liver or intestine (Chen et al., 2010). Our
unpublished data also suggests that zyklopen is expressed in brain
and neural retina, but not RPE cells.
Iron levels are managed by an iron-responsive mechanism
involving iron regulatory proteins (IRPs, IRP1 and IRP2) which
serve to register intracellular iron status. This regulation allows
individual cells to regulate iron uptake, sequestration and export
depending on their iron status. Under conditions of iron star-
vation, IRP1 and IRP2 are activated for high affinity binding to
multiple “iron-responsive elements” (IREs) in the 3′-untranslated
region of TfR mRNA and to a single IRE in the 5′-untranslated
region of the mRNAs encoding both H- and L-ferritin chains.
This stabilizes TfR mRNA (Binder et al., 1994) and inhibits fer-
ritin mRNA translation (Muckenthaler et al., 1998). Conversely,
failure of IRPs to bind to cognate IREs in iron-replete cells leads
to degradation of TfR mRNA and synthesis of ferritin.
IRON IMPORT INTO THE RETINA
The blood–retinal barrier isolates the retina from the blood-
stream. The intercellular tight junctions of the neuroretinal
vasculature and RPE resulting in independent barriers prevent
intercellular diffusion, thereby protecting both sides of the retina
from systemic circulation.
TRANSFERRINMEDIATED TRANSPORT
When bound to transferrin in the choroidal circulation, iron is
taken up by high affinity TfR at the basolateral surface of the RPE.
Then, this complex is internalized into a low pH endosome where
iron is dissociated from transferrin. After export from the endo-
some, iron enters a cytoplasmic pool of labile iron where it can
bind to ferritin or be transported for further use. Whether RPE
cells transport iron apically toward the retina is not clear. A poten-
tial alternative route for iron transport into the retina is through
the retinal vascular endothelial cells. Evidence suggests that ferro-
portin is expressed by these cells, which may transport iron into
the retina in a process regulated by hepcidin (Hadziahmetovic
et al., 2011a). Once iron enters the retina, it is likely to bind
transferrin. The vitreous humor and aqueous fluid contain large
amounts of transferrin (Hawkins, 1986; Yu and Okamura, 1988;
Tripathi et al., 1990). Experiments with intravitreal injection of
labeled fucose or tyrosine suggest that the vitreous transferrin
is partially synthesized locally in the eye (Laicine and Haddad,
1994), in part by the ciliary body (Rodrigues et al., 1998). The
iron-transferrin complex can then be taken up by the TfRs on the
photoreceptor inner segments (Yefimova et al., 2000). The pho-
toreceptor inner segments of adult rat retinas are immunolabled
for TfR, which probably bind and internalize the iron-transferrin
complex in the photoreceptor matrix.
DIVALENT METAL TRANSPORTER-1
Divalent metal transporter-1 (DMT1), a proton symporter,
moves one atom of ferrous iron and a proton in the same direc-
tion (Gunshin et al., 1997). DMT1 is located on the apical surface
of intestinal epithelial cells and transports dietary free iron, upon
reduction from the ferric to ferrous form, from the luminal sur-
face into the enterocytes (Rouault and Cooperman, 2006). DMT1
is located on the endosome and transports iron from the endo-
some into the cytoplasm in most other cells in the body (Rouault
and Cooperman, 2006). Some studies have localized DMT1 in
rat brain blood vessels (Burdo et al., 2001), while others have
detected it in neurons but not vascular cells (Gunshin et al.,
1997). While this issue remains controversial, its potential local-
ization in blood vessel suggests that DMT1 may mediate iron
transport to and/or from the brain. Belgrade rats with a muta-
tion in DMT1 have a hypochromic, microcytic anemia and less
iron in their brains, consistent with a role for DMT1 in brain iron
transport (Burdo et al., 1999). In the retina, we detected strong
DMT1 immunolabel in rod bipolar cell bodies, rod bipolar cell
axons, horizontal cell bodies, and photoreceptor inner segments.
However, the importance of DMT1 for iron import into these cells
is currently unclear.
DEXRAS
Dexras1, a 30 kDa G-protein with close homology to the Ras
subfamily and localized predominantly to the brain, can be
induced by the activation of glutamate-NMDA receptors to sig-
nal the uptake of iron in neurons (Cheah et al., 2006). The
activation of glutamate-NMDA receptors stimulates nitric oxide
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synthase which binds to the nitric oxide synthase 1 adapter
protein, CAPON, and delivers nitric oxide to Dexras1 causing
S-nitrosylation of Dexras1. In the down-stream pathway, Dexras1
interacts with peripheral benzodiazepine receptor-associated pro-
tein (PAP7), which binds to DMT1 to induce iron uptake. It
has been hypothesized that NMDA neurotoxicity is caused by
increased iron uptake following induction of this signaling cas-
cade, since iron chelation in neuronal cultures protects against
NMDA neurotoxicity. Consistent with this mechanism, Dexras1
knockout mice are protected against retinal ganglion cell death
induced by intravitreal NMDA injection (Chen et al., 2013).
IRON STORAGE
FERRITIN
Iron is primarily stored as cytosolic ferritin which is capable of
holding as many as 4500 iron molecules in the ferric state in
its central core. H-ferritin has ferroxidase activity allowing it to
rapidly accumulate Fe3+ in its central core (Aisen et al., 2001)
while L-ferritin does not (Levi et al., 1994). The distribution of
iron and ferritin has been characterized in the adult rat retina.
Proton-induced X-ray emission identified the largest amounts
of heme and non-heme iron in the inner segments of photore-
ceptors, the RPE, the choroid, the inner nuclear layer, and the
ganglion cell layer (Yefimova et al., 2000). Iron was present in
somewhat lesser, but still significant amounts in the photorecep-
tor outer segments (Yefimova et al., 2000; Ugarte et al., 2012).
Interestingly, immunohistochemistry studies have demonstrated
a similar distribution pattern of retinal ferritin. The exception is
that iron, but not much ferritin, is contained in the photoreceptor
outer segment. Also, ferritin levels are regulated by IRPs (Hentze
and Kühn, 1996). IRPs inhibit ferritin translation by binding to
ferritin mRNA in iron-depleted cells to regulate ferritin levels.
MITOCHONDRIAL FERRITIN
Mitochondrial ferritin (TfR) is structurally similar to H-ferritin
but localized to the mitochondria (Levi et al., 2001). MtF was
detected by immunohistochemistry in the photoreceptor inner
segments and diffusely throughout the inner retina (Hahn et al.,
2004b). In order to confirm mitochondrial localization, anti-
MtF was co-labeled with an antibody specific for the ATPase in
Complex V of the electron transport chain ofmitochondria. Label
co-localized to the inner segment ellipsoids, the location of the
mitochondria, but not the inner segment myoid.
IRON EXPORT
CERULOPLASMIN
Ceruloplasmin, a multicopper oxidase with ferroxidase activity,
functions as an antioxidant by oxidizing iron from its Fe2+ to
Fe3+ state, thus preventing oxidative damage induced by Fe2+
mediated free radical generation by the Fenton Reaction (Osaki,
1966). Additionally, by oxidizing iron from its Fe2+ to Fe3+,
ceruloplasmin facilitates iron export out of the cell since only
ferric iron can be taken up by transferrin in the circulation
(Osaki, 1966); extracellular ferroxidases including ceruloplasmin
are important in the ferroxidation which is thus necessary to ini-
tiate efficient iron export, probably through the generation of an
ion gradient (Sarkar et al., 2003).
Two forms of ceruloplasmin have been identified: the secreted
form and themembrane-anchored GPI-linked form. The secreted
form is the predominant form made by the liver while the GPI-
linked form is the predominant form found in the brain (Patel
et al., 2000). Both forms of ceruloplasmin are present in mouse
and human retina (Chen et al., 2003). The secreted form was also
identified in the mouse and human RPE (Hahn et al., 2004b).
Immunohistochemistry demonstrated that ceruloplasmin pro-
tein is located diffusely throughout the retina. The strongest signal
in mouse retina was found in the Müller cells. As confirmed by
Western analysis, ceruloplasmin is also present in the aqueous,
vitreous and retina of a normal human eye (Chen et al., 2003).
Ceruloplasmin has been found to be upregulated in the retina
in multiple pathological conditions including light damage, optic
nerve crush, glaucoma, and diabetes (Levin and Geszvain, 1998;
Chen et al., 2003; Miyahara et al., 2003; Farkas et al., 2004;
Gerhardinger et al., 2005). In 10-week-old male BALB/c mice
exposed to bright fluorescent light or room light for 7 h, retinal
ceruloplasmin levels were increased in light exposed retinas com-
pared to controls. Again, the strongest label was observed in the
Müller cells (Chen et al., 2003). It was postulated that upregula-
tion of ceruloplasmin following light damage serves to protect the
eye from light-induced oxidative attack. Both the direct antioxi-
dant effect of ceruloplasmin as well as its iron export function
may be important for protection against light damage.
In rats subjected to intraorbital optic nerve crush, cerulo-
plasmin mRNA levels were found to be upregulated relative to
controls. Ceruloplasmin mRNA localized to the inner nuclear
and ganglion cell layers demonstrated by in situ hybridization.
Immunohistochemistry localized ceruloplasmin protein in spo-
radic cells within the nerve fiber layer of untreated retinas (Levin
and Geszvain, 1998). In monkeys with experimental glaucoma,
microarray assay has demonstrated ceruloplasmin upregulation
and immunohistochemical studies have localized the ceruloplas-
min to Müller cells (Miyahara et al., 2003). In human retinas with
glaucoma, there are increased ceruloplasmin levels in the inner
plexiform layer, ganglion cell layer, and nerve fiber layer compared
with controls by immunohistochemistry (Farkas et al., 2004).
In addition, ceruloplasmin has also been shown to be upreg-
ulated in the diabetic rat retina (Gerhardinger et al., 2005).
Similarly, ceruloplasmin is upregulated in the aqueous and vitre-
ous of rabbit eyes with endotoxin-induced ocular inflammation
(McGahan and Fleisher, 1986). Ceruloplasmin is additionally
upregulated secondary to oxidative stress to the lens, as confirmed
by exposure of immortal murine lens epithelial cells to the oxidant
tert-butyl hydroperoxide (Li et al., 2004).
HEPHAESTIN
Hephaestin (Heph), another multicopper ferroxidase, is a
homolog of ceruloplasmin with 50% amino acid identity (Vulpe
et al., 1999). Similar to ceruloplasmin,Heph facilitates iron export
by oxidizing ferrous iron to its ferric state thereby facilitating its
transport across the plasma membrane and uptake by transferrin
in the extracellular space (Vulpe et al., 1999). Vulpe et al identified
Heph through characterization of sex-linked anemia (sla) mouse
which has a Heph mutation that severely decreases its ferroxi-
dase activity. In this mouse, decreased Heph ferroxidase activity
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resulted in reduced iron export from intestinal epithelial cells,
yielding an anemic mouse.
The presence of heph mRNA has been confirmed by RT-PCR
in mouse and human RPE cells, and the localization of Heph
protein also has been demonstrated by immunohistochemistry
in Müller cells in the retina with the greatest amounts in the
Müller endfeet adjacent to the internal limiting membrane (Hahn
et al., 2004b). The importance of ceruloplasmin and Heph in iron
export from the retina is demonstrated in mice with combined
deficiency of these two enzymes that results in age-dependent
iron accumulation in both RPE and retina (Hahn et al., 2004b).
In these mice, Perls’ staining revealed iron accumulation in the
photoreceptor outer segments and RPE, and electron micro-
graphs showed electron-dense vesicles in the RPE (Figure 1).
These vesicles were likely lysosomes or endosomes, sometimes
fused with melanosomes. X-ray spectroscopy demonstrated that
these vesicles had four times more iron content compared to other
intracellular structures. Immunohistochemistry revealed H- and
L-ferritin were present in rod bipolar cell termini in the inner
plexiform layer. Additionally, L-ferritin was found in the inner
sections of the outer plexiform layer and the RPE. H-ferritin
label showed strongest signal in the photoreceptor inner seg-
ments and axons in the outer part of the outer plexiform layer
(Hahn et al., 2004a). In contrast to cytosolic H- and L-ferritin,
MtF has not been shown to be IRP-regulated. But MtF was
increased in the photoreceptor inner segments of Cp−/− and
Cp−/−Heph−/Y mice (Hahn et al., 2004a). In Cp−/−mice, MtF
colocalized with a mitochondria-specific antibody to the inner
segment ellipsoid rather than the inner segment myoid. The ele-
vated iron level in these mice causes oxidative stress (detected
by increased isoprostane levels) resulting in retinal degenera-
tion characterized by RPE hypertrophy and autofluorescence,
sub-RPE deposits, photoreceptor death, and subretinal neovascu-
larization. This degeneration is prevented by the oral iron chelator
deferiprone (Hadziahmetovic et al., 2011b).
FERROPORTIN AND HEPCIDIN
Evidence suggests that Ferroportin (Fpn), a transmembrane pro-
tein, exports iron out of the cell in cooperation with ferroxidases
Cp or Heph which convert it to ferric form (Harris et al., 1999;
Vulpe et al., 1999). Ceruloplasmin increased iron export from
Xenopus oocytes in the presence of Fpn (Donovan et al., 2000;
McKie et al., 2000). This effect was observed when ceruloplasmin
was added to the medium (McKie et al., 2000). Ceruloplasmin
also exports iron from macrophages in vitro, but only when
tissue culture oxygen levels mimick in vivo tissue oxygen lev-
els rather than atmospheric oxygen levels (Sarkar et al., 2003).
Furthermore, stable expression of Fpn in J774 cells, a macrophage
cell line, increases iron efflux after erythrophagocytosis (Knutson
et al., 2005). Conditional knockout of Fpn in mouse villus ente-
rocytes has shown that the protein functions as the major, if
not only, iron exporter from the duodenum to the circulation
(Donovan et al., 2005).
In the mouse retina, ferroportin immunolocalizes to the RPE,
photoreceptor inner segments, inner and outer plexiform lay-
ers, and ganglion cell layer. In mice deficient in Cp and Heph,
ferroportin immunoreactivity increases, presumably due to an
iron-mediated increase in levels of ferroportin transcription
(Hahn et al., 2004a).
Hepcidin (Hepc) is a 25 amino acid peptide found in human
plasma and urine and produced by the liver (Krause et al., 2000;
Park et al., 2001). It was shown that Hepc has anti-microbial
activity, and its expression is upregulated by infection, inflam-
mation and iron (Pigeon et al., 2001; Nicolas et al., 2002). Hepc
binds to ferroportin, triggering its internalization and lysosomal-
dependent degradation (Nemeth et al., 2004; Knutson et al.,
2005). Liver secretes Hepc into the circulation when iron is in
excess. The Hepc then triggers degradation of ferroportin in
enterocytes and macrophages, maintaining homeostasis by pre-
venting iron release into the circulation. In the retina, Hepc
can also be synthesized by Muller cells, photoreceptors and RPE
and is upregulated by inflammation (Gnana-Prakasam et al.,
2008) and elevated iron levels (Hadziahmetovic et al., 2011b).
Ferroportin degradation in vascular endothelial cells and RPE is
triggered by Hepc, preventing further iron transport into the neu-
ral retina, which is consistent with Hepc knockout mice exhibit-
ing increased retinal iron and subsequent retinal degeneration
(Hadziahmetovic et al., 2011b). Bmp6 is crucial for regulation of
systemic iron homeostasis through Hepc. Bmp6 was detected in
RPE and its receptors are expressed in the neurosensory retina. In
cultured RPE cells, Bmp6 was down-regulated by oxidative stress
and up-regulated by iron. Bmp6 secreted from the RPE cells likely
binds Bmp6 receptors in the neurosensory retina up-regulating
Hepc, because both intravitreal and subretinal injection of Bmp6
up-regulated Hepc within the neurosensory retina but not within
the RPE. Bmp6−/− mice had age-dependent retinal iron accu-
mulation and degeneration. Postmortem RPE from patients with
early AMD exhibited decreased Bmp6 levels. The diminished
Bmp6 levels observed in RPE cells in early AMD may contribute
to iron build-up in AMD. This may in turn propagate a vicious
cycle of oxidative stress and iron accumulation, exacerbating
AMD and other diseases with hereditary or acquired iron excess
(Hadziahmetovic et al., 2011c).
DISRUPTION OF IRON HOMEOSTASIS AND OXIDATIVE
DAMAGE
Increased intraocular iron has been shown to cause oxidative
injury to the retina as shown when intravitreous iron sulfate
is administered to adult C57BL/6 mice, resulting in increased
superoxide radicals in photoreceptor inner segments, lipid per-
oxidation of the photoreceptors and retinal degeneration (Rogers
et al., 2007). With a higher concentration of iron sulfate injection,
thesemice exhibited an irregular outer border of the outer nuclear
layer suggesting photoreceptor damage. Ceruloplasmin-deficient
mice have hereditary iron overload and also show features of
retinal degeneration. Eighteen-month-old Cp−/− mouse retinas
showed mild degeneration of the inner nuclear layer including
condensed chromatin and dark cytoplasm in the cells (Patel et al.,
2002). Patients with ceruloplasmin deficiency from the hereditary
disease aceruloplasminemia also have retinal iron accumulation
with retinal degeneration (Dunaief et al., 2005). The degeneration
primarily involves RPE cells, with hypo and hyperpigmenta-
tion, autofluorescence, sub-RPE drusen and subretinal drusenoid
deposits (Wolkow et al., 2011).
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FIGURE 1 | Adult (6-month-old) Cp−/−Heph−/Y RPE and photoreceptors
accumulate iron. (A–C) 6-month-old WT (A), Cp−/− (B), and Cp−/−Heph−/Y
(C) retinas Perls’ stained for iron (blue) and counterstained with
hematoxylin/eosin. (D) High magnification of Prussian blue Perls’ label in
6-month-old Cp−/−Heph−/Y RPE. (E and F) Light photomicrographs of
6-month-old Cp−/−Heph−/Y (E) and WT (F) retinas after DAB enhancement
(brown) of Perls’ stain. (G and H) Electron micrographs of RPE from
6-month-old Cp−/−Heph−/Y (G) and WT (H) eyes. Only the Cp−/−Heph−/Y
RPE (G) contains electrondense vesicles (∗) sometimes fused with
melanosomes. Reprinted from Hahn et al. (2004b).
Our team has found that mice with age-dependent iron accu-
mulation from combined deficiency of Cp and Heph also exhibit
retinal degeneration (Hahn et al., 2004b). In these mice, RPE
cells in up to 75% of a histologic section across the entire
retina were severely hypertrophic, hyperplastic, and necrotic
with local photoreceptor loss and subretinal neovascularization
revealed by light microscopy. Electron microscopy of the hyper-
trophic RPE revealed excessive accumulation of phagosomes and
lysosomes which appear to contain undigested outer segments
(Figure 2).
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FIGURE 2 | Cp−/−Heph−/Y (9-mon-old) mice have retinal degeneration.
(A) Light photomicrograph of WT retina. (B and C) Cp−/−Heph−/Y retina
has focal patches of hypertrophic RPE cells in some regions (B) and
confluent hypertrophic RPE cells in other areas (C). (D) In an area of RPE
hyperplasia (demarcated by arrowheads), Cp−/−Heph−/Y retinas have local
photoreceptor degeneration [demarcated by arrows in the outer nuclear
layer (ONL)] and subretinal neovascularization (red∗). (E) In an area of
hypertrophic, hyperplastic (area demarcated by arrowheads) RPE cells,
(Continued)
FIGURE 2 | Continued
a necrotic RPE cell also observed by electron microscopy (Left Inset) is
present. Within the area of RPE hyperplasia, there is local photoreceptor
thinning and subretinal neovascularization (red∗) visible as small vessels
containing erythrocytes (Right Inset). The hyperplastic RPE have formed a
localized cyst (Cy). (F) Electron micrograph of WT RPE. Br, Bruch’s
membrane; AM, apical microvilli; OS, photoreceptor outer segments. (G)
Electron micrograph of Cp−/−Heph−/Y RPE overloaded with phagosomes
and lysosomes containing photoreceptor outer segments at various stages
of digestion. Some of these lysosomes (∗) contained multilamellar
structures characteristic of outer segment membranes (Inset). (H) Electron
micrograph of Cp−/−Heph−/Y deposits between RPE and Bruch’s
membrane containing wide-spaced collagen (∗). (Scale bars: A–E, 50μm; F
and G, 2μm; H, 500nm.) Reprinted from Hahn et al. (2004b).
Disrupted RPE-photoreceptor interactions can cause
iron overload that probably exacerbates retinal degeneration
(Yefimova et al., 2002). In Royal College of Surgeons (RCS)
rats with a mutation in the receptor tyrosine kinase Mertk, the
RPE is unable to phagocytise shed outer segments, resulting in
a layer of undigested outer segment tips in the subretinal space
(Yefimova et al., 2002). This disrupts the normal function of
RPE-photoreceptor interactions, including transferrin diffusion,
and leads to increased non-heme iron levels in the interpho-
toreceptor debris layer, and diminished transferrin levels in the
photoreceptor layer, both of which promote photoreceptor loss
at post-natal day 20.
RETINAL DISORDERS RESULTING FROM ABNORMAL
RETINAL IRONMETABOLISM
Disrupted iron homeostasis in hereditary and acquired diseases
can result in iron overload and retinal disease. Putative retinal
iron transport mechanisms and several diseases affecting them are
summarized in Figure 3.
AGE-RELATEDMACULAR DEGENERATION
AMD is the leading cause of irreversible blindness in people over
age 65 in developed nations (Leibowitz et al., 1980; Klein et al.,
1995). In early stage, manifestations of the disease include drusen
deposits associated with the RPE. As the disease progresses,
patients may develop geographic atrophy in dry AMD or non-
exudative AMD; choroidal neovascularization in wet or exudative
AMD. Oxidative stress and radical mediated damage are impli-
cated in the pathogenesis of AMD (Beatty et al., 2000; Zarbin,
2004). In a large clinical trial, patients with intermediate stage
AMD given dietary supplements of antioxidants including beta-
carotene, vitamin C, vitamin E, and zinc, experienced reduced
progression to advanced AMD. This suggests oxidative stress is an
important factor involved in AMD pathogenesis (AREDS, 2001).
Iron may be a major source of oxidative stress in AMD. Perls’
stain detected increased iron in AMD-affected maculas compared
to healthy age-matchedmaculas (Hahn et al., 2003), specifically in
the RPE and Bruch’s membrane of early AMD, geographic atro-
phy, and exudative AMD patients. Analysis of the postmortem
macula of a 72-year-old white male with advanced geographic
atrophy demonstrated iron overload not only in the RPE but also
in the photoreceptor layer. Perls’ stain detected iron in the pho-
toreceptors and internal limiting membrane along with elevated
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FIGURE 3 | Schematic diagram showing the retinal layers (A), with
enlarged view of the RPE and potential routes of iron traffic (B). Several
diseases that disrupt retinal iron transport are indicated in red. Proteins
involved in iron transport are illustrated: Cp, ceruloplasmin; DMT1, Divalent
metal tranporter-1; Fe, iron; Fe2+, ferrous iron; Fe3+, ferric iron; Fpn,
ferroportin; Frat, Frataxin; HFE, histocompatability leukocyte antigen class
I-like protein involved in iron homeostasis; Hp, Hephaestin; Tf, transferrin;
TfR, Transferrin receptor.
levels of ferritin and ferroportin in the photoreceptors and inter-
nal limiting membrane whereas the normal maculas were only
weakly labeled with anti-ferritin and anti-ferroportin antibody
(Dentchev et al., 2005). Mean aqueous humor iron levels were
elevated by more than two-fold in dry AMD patients undergo-
ing cataract surgery relative to controls, supporting the assertion
that iron levels are elevated in AMD eyes (Jünemann et al.,
2013).
Although iron accumulation has been detected in AMD reti-
nas, whether it is a cause or consequence of AMD remains elusive.
However, there are several lines of evidence indicating that iron
directly contributes to AMDpathogenesis. First, iron accumulates
with age increase (Hahn et al., 2006). Eyes from younger donors
(less than 35 years old) and older donors (older than 65 years old)
were dissected and separated into the retina and RPE/choroid.
Atomic absorption spectrophotometry of retinas showed a sig-
nificant increase in iron levels in the retinas of older compared to
younger eyes. Much of this iron in the neural retina is likely to
be in the photoreceptor layer, which is the region containing the
most iron in rat retinas (Ugarte et al., 2012).
Second, iron is a potent generator of radicals and results in
photoreceptor/RPE toxicity when locally elevated in conditions
such as ocular siderosis. Although siderosis causes pan-retinal
degeneration but not drusen, geographic atrophy, or CNV, this
variation may be attributed to the differences in route of iron
delivery and spatial and temporal patterns of iron accumula-
tion. Third, mice with double deficiency of Cp and Heph and
subsequent age dependent retinal iron accumulation develop a
retinal degeneration with several features of AMD (Hahn et al.,
2004b). These features include sub-RPE wide-spaced collagen
that is normally found in association with drusen in humans,
RPE lysosomal inclusions, and RPE death. Histologically, these
mice show focal photoreceptor loss and subretinal neovascular-
ization similar to the advanced stage of AMD (Figure 2). Fourth,
a patient with iron overload resulting from aceruloplasminemia
had early-onset subretinal deposits similar to drusen found in
AMD patients (Dunaief et al., 2005). Finally, transferrin is upreg-
ulated in AMD patients suggesting altered iron regulation or
levels (Chowers et al., 2006). Microarray analysis and RT-PCR on
postmortem retinas of AMD patients and age-matched controls
found a 3.5-fold increase in transferrin mRNA levels in dry AMD
relative to retinas without AMDand 2.1-fold increase in wet AMD
vs. retinas without AMD. Western blot analysis showed a 2.1-fold
increase in transferrin levels in AMD retinas compared to retinas
without AMD. In these AMD patients, immunohistochemistry
detected more transferrin signal in AMD retinas, especially in the
photoreceptors, Müller cells, and drusen.
While the mechanism of iron accumulation in AMD is
unknown, plausible culprits include inflammation, hypoxia, and
oxidative stress, all of which contribute to AMD pathogenesis.
Inflammation can cause cellular iron sequestration through IL-
6 mediated upregulation of hepcidin (Ganz and Nemeth, 2009).
Hypoxia can lead to increased iron uptake through HIF-mediated
upregulation of DMT1, a cellular iron importer (Wang et al.,
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2010). Oxidative stress can upregulate TfR, another cellular iron
importer (Fonseca et al., 2003). Further, hemorrhage in wet AMD
causes iron transfer from degraded red blood cells to the retina
(Bhisitkul et al., 2008).
ACERULOPLASMINEMIA
Aceruloplasminemia is a rare adult-onset autosomal recessive
disease caused by mutations in the ceruloplasmin gene on chro-
mosome 3q (Harris et al., 1995). Iron export from certain tissues
is disrupted in these patients because ceruloplasmin normally
facilitates iron export by converting it from Fe2+ to Fe3+, the
form of iron that can be loaded onto transferrin. The retina,
brain, and pancreas become iron overloaded in patients with
aceruloplasminemia. Clinically, aceruloplasminemia includes the
triad of retinal degeneration, dementia, and diabetes (Yamaguchi
et al., 1998). The retinal findings in aceruloplasminemia have
only been reported in a few patients. All of them have showed
retinal pigmentary abnormalities, and one had subretinal macu-
lar deposits similar to drusen (Dunaief et al., 2005). Fluorescein
angiography (FA) showed RPE atrophy resulting in window
defects in the macula. The drusen-like opacities seen by ophthal-
moscopy caused blocked fluorescence on the FA. The drusen-like
deposits were first observed at age 47 and became smaller and
spread out in a centrifugal fashion over the subsequent 9 years.
Interestingly, the patient had yellow pingueculae in both eyes and
Perls’ Prussian blue staining revealed iron overloaded epithelial
cells in the pinguecula. Histopathology of this case revealed RPE
iron accumulation, hypertrophy, hyper and hypo-pigmentation,
autofluorescence, sub-RPE and sub-retinal drusen.
Similarly, histopathology in mice with combined deficien-
cies of Cp and Heph has been studied (Hahn et al., 2004b).
By 6–9 months, these mice demonstrated RPE iron accumula-
tion and hypertrophy. Focal RPE hyperplasia and necrosis, local
photoreceptor loss, and subretinal neovascularization were also
observed in some mice. Electron microscopy of hypertrophic RPE
showed increased phagosomes, lysosomes, and sub-RPE deposits
of wide-spaced collagen, resembling some hallmarks of AMD
(Figure 2).
HEMOCHROMATOSIS
There are two types of hemochromatosis: primary and sec-
ondary. As a hereditary disease, primary hemochromatosis is
characterized by excessive iron accumulation in the heart, pan-
creas, liver, and other tissues (Pietrangelo, 2006). Clinically, this
results in cardiomyopathy, diabetes, cirrhosis, arthritis, testic-
ular failure, and darkening of the skin. Several mutations can
lead to hereditary hemochromatosis. The most common muta-
tion resides in the histocompatibility leukocyte antigen class
I-like protein involved in iron homeostasis (HFE) gene prod-
uct (Feder et al., 1998). This protein normally binds the TfR
and forms a stable complex, thus lowering the affinity of the
receptor for transferrin. Themutation affects complex formation,
resulting in more transferrin binding to TfR and subsequently
more iron import into the cell. HFE also regulates the expression
of Hepc. Another genetic form of hereditary hemochromato-
sis results from mutation in ferroportin, reducing iron export
from cells (Pietrangelo, 2004). Hereditary hemochromatosis can
also result from mutations in Hepc, hemojuvelin (responsible for
juvenile hemochromatosis), or TfR 2 (Pietrangelo, 2005; Nemeth
and Ganz, 2006). In three cases with hereditary hemochromato-
sis, retinal abnormalities include drusen and iron in the peri-
papillary RPE, ciliary epithelium, and sclera (Roth and Foos,
1972).
Evidence from mice supports the possibility that primary
hemochromatosis may result in retinal iron accumulation and
degeneration. The mouse retina expresses HFE and HJV (Martin
et al., 2006; Gnana-Prakasam et al., 2009b), and in knockouts
of each of these genes, the retina accumulates iron and exhibits
degeneration (Gnana-Prakasam et al., 2009a, 2012). In addition,
the RPE exhibits a proliferative phenotype in mice lacking these
genes.
Secondary hemochromatosis, or acquired hemochromatosis,
results from iron intake during the process of multiple trans-
fusions that are administered to patients with sickle cell ane-
mia and thalassemia. Defects in Bruch’s membrane underlying
the RPE, called angioid streaks, can also be observed in these
patients. However, it is difficult to differentiate the effects of iron
overload, intraocular hemorrhage, and chelation therapy on the
retina. It is possible that these patients have retinal iron overload.
Alternatively, if local control of iron homeostasis in the retina pre-
vents excess iron accumulation despite systemic iron overload,
retinal iron level may not be affected. Retinal iron quantifica-
tion and localization in postmortem eyes will help to address these
issues.
FRIEDREICH’S ATAXIA
Friedreich’s ataxia (FRDA) is an autosomal recessive neurode-
generative disease characterized by progressive ataxia. In most
patients with FRDA, a gene encoding the mitochondrial protein
frataxin contains a mutation that leads to progressive iron accu-
mulation in mitochondria. Most patients with Friedreich’s ataxia
can develop a late-onset progressive optic neuropathy, indicating
ganglion cell involvement (Porter et al., 2007). A published case in
a 59-year-old woman with FRDA documented severe optic neu-
ropathy with rapid-onset catastrophic vision impairment (Porter
et al., 2007). Color fundus photos showed a pale optic disc and
scattered fleck-like yellow deposits throughout the macula. These
yellowish deposits were auto-fluorescent, suggesting the presence
of lipofuscin. Additionally, a pigmentary retinopathy has also
been associated with FRDA.
PANTOTHENATE KINASE-ASSOCIATEDNEURODEGENERATION (PKAN)
Pantothenate kinase-associated neurodegeneration (PKAN), an
autosomal recessive neurodegenerative disorder which used to
known as the Halervorden-Spatz syndrome, is characterized by
iron accumulation in the brain resulting in dystonia, choreoa-
thetosis, rigidity, spasticity, tremor, dementia, or psychomotor
retardation (Koeppen and Dickson, 2001). The disease is due
to mutations in the pantothenate kinase 2 gene which produces
phosphopantothenate (Zhou et al., 2001). Phosphopantothenate
condenses with cysteine in the production of coenzyme A. The
mutation results in deficient phosphopantothenate and increased
cysteine which binds iron. As a result, iron accumulates in
areas of the brain normally containing the most iron, including
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the medial globus pallidus and subtantia nigra. In the retina
where coenzyme A is in the highest demand, disrupted mem-
brane biosynthesis is likely to occur. Rod photoreceptors are
constantly shedding outer segments and synthesizing new mem-
brane discs and deficit of CoA may explain the retinopathy
resulting from PKAN. Clinical features of PKAN include child-
hood onset, dystonia or psychomotor retardation (Koeppen and
Dickson, 2001). Retinal features in these patients include a pig-
mentary retinopathy with attenuated arterioles, foveal hyper-
pigmentation, posterior pole depigmentation, bone spicules,
bull’s eye maculopathy, and flecked retina (Newell et al., 1979;
Luckenbach et al., 1983). The flecks and macular annulus corre-
lated to melanolipofuscin-contaning macrophages. Nearby RPE
cells were hypertrophic with aggregated melanolipofuscin inside.
The bone-spicule pattern seen by ophthalmoscopy corresponded
to melanin pigment in RPE cells found around the retinal vas-
culature. Histology demonstrated total loss of photoreceptor
outer and inner segments. Mice with a knockout of pantothen-
ate kinase 2 also show photoreceptor degeneration (Kuo et al.,
2005).
SIDEROSIS
Ocular siderosis is a sight-threatening condition resulting from
deposition of iron in intraocular tissue that leads to oxida-
tive damage from radicals generated by ferrous iron. The most
common cause is an intraocular foreign body, but it can also
due to an intraocular hemorrhage. Clinical manifestations of
this disease include corneal iron deposition, iris heterochro-
mia, pupillary mydriasis, failure of accommodation, anterior
subcapsular cataract, or lens discoloration. If there is involve-
ment of the trabecular meshwork and Schlemm’s canal, sec-
ondary glaucoma can develop (Cibis et al., 1959; Talamo et al.,
1985; Sneed, 1988). In the retina, RPE clumping and atrophy
can occur as well as retinal arteriolar narrowing and retinal
detachment. Initially, electroretinography (ERG) a- and b- wave
amplitude may increase, but as the siderosis progresses and pho-
toreceptors degenerate, there is gradual decrease in amplitude
(Knave, 1969).
Animal models of siderosis have shown both histopathologic
and functional abnormalities in the retina. After 10 days of
solid iron foreign body insertion into rabbit vitreous, degenera-
tion of the outer nuclear layer and RPE was observed (Declercq
et al., 1977). Consistent with morphological change, ERG mea-
surements also showed a reduction in both the a- and b-wave
amplitudes under both scotopic and photopic conditions. Cibis
et al. studied pathological specimens of patients who had ocular
siderosis and hemosiderosis. Sequelae of intraocular iron over-
load include contraction bands in the vitreous body and inner
surface of the retina, proliferation and obliteration of blood ves-
sels, retinal detachment, and retinal degeneration (Cibis et al.,
1959).
In ocular siderosis, iron accumulates in the eye because it
has been introduced acutely. With aging and disease where iron
transport is dysregulated, iron accumulation is slower and more
chronic. Yet, whether the iron accumulation is acute or chronic,
the photoreceptors and RPE are the cell types most susceptible to
iron-induced damage or death.
SUBRETINAL HEMORRHAGE
Subretinal hemorrhage in the macula may disrupt vision function
in a number of diseases including AMD, myopic degeneration,
angioid streaks, and ocular histoplasmosis. In a study of patients
with intraretinal and subretinal hemorrhage, it was shown that
the visual acuity loss depends on hemorrhage size and ability of
the tissue to clear the blood (Gillies and Lahav, 1983).
The possible mechanisms for vision dysfunction caused by
subretinal hemorrhage include direct iron toxicity to photorecep-
tors, iron toxicity to the RPE, isolation of the photoreceptors from
the RPE, cell migration and proliferation in the subretinal space,
or proliferation of a fibrovascular membrane (Gillies and Lahav,
1983). Autologous blood injection into the subretinal space of
albino rats and rabbits resulted in progressive degeneration of the
photoreceptor with edematous change, and iron accumulation in
the RPE and photoreceptor outer segments (Glatt andMachemer,
1982). Deferoxamine, an iron chelator, has been shown to pro-
tect retina from toxicity caused by subretinal blood in these rats
(Youssef et al., 2002). In a similar experimental model using
rabbits, iron was identified with Perls’ staining in RPE and pho-
toreceptors, and triamcinolone reduces photoreceptor apoptosis
(Bhisitkul et al., 2008). Oxyhemoglobin is believed to be a medi-
ator responsible for the pathology of blood in the retina. In vitro,
experiments with oxyhemoglobin demonstrated that, when ele-
vated, led to lipid peroxidation in retinal tissues (Ito et al., 1995).
The hemoglobin-binding protein hemopexin may protect retina
from heme-mediated toxicity. RPE cells bind and internalize the
heme–hemopexin complex from the retina and thus facilitate
clearance of sub- or intra-retinal blood (Hunt et al., 1996).
POTENTIAL THERAPEUTICS
Since iron-mediated oxidative damage may be involved in the
pathogenesis of AMD, it is reasonable to assume antioxidants and
iron chelators may reduce the incidence and progression of AMD.
It has been shown by Age-Related Eye Disease Study (AREDS)
that supplemental zinc, vitamin C, vitamin E, and β-carotene can
reduce the risk of AMD progression, and it is likely that additional
antioxidants may further protect or slow the AMD progression.
Given that iron is one of the most potent sources of oxidative
damage via hydroxyl radical production in the Fenton reaction,
and since the antioxidants used in the AREDS study may not be
able to eliminate all of the hydroxyl radical generated by iron,
iron chelators may prove to be a useful complement to AREDS
vitamins. Several reports indicate that iron chelation may be ben-
eficial in neurological diseases such as Alzheimer’s disease and
Parkinson’s disease, Huntington’s disease and FRDA (Richardson,
2004; Zheng et al., 2005). It is plausible that iron chelation may
also be effective in treating retinal disease associated with iron
overload. Iron-binding proteins could also be therapeutically use-
ful, as transferrin has been shown to protect against hereditary
retinal degeneration in mice (Picard et al., 2010).
However, there are challenges with choosing clinically available
iron chelators. Ideally, the iron chelator for retinal degeneration
therapy should be absorbed easily in sufficient volume through
the GI tract, and transit the blood–retinal barrier efficiently. Such
chelators are likely to be uncharged, lipid soluble, and of small
molecular size to facilitate passage through the blood–retinal
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barriers (Maxton et al., 1986; Kalinowski and Richardson, 2005).
Additionally, the ideal chelator might exclusively bind iron but no
other biologically important divalent metals such as Zn2+ (Liu
and Hider, 2002).
Currently, the clinically available iron chelators include defer-
oxamine, deferiprone, and deferasirox. Another potentially ther-
apeutic iron chelator is salicylaldehyde isonicotinoyl hydrazone
(SIH). The advantages and disadvantages of each of these chela-
tors are summarized by Mehta (Mehta and Dunaief, 2012).
Previously, in vitro experiments demonstrated iron in the RPE
and Bruch’s membrane can be chelated with deferoxamine. A
recent study (Obolensky et al., 2011) demonstrated that treat-
ment with zinc-deferoxamine reduced retinal oxidative stress
and enhanced photoreceptor survival, leading to both functional
and structural rescue in the rd10 model of retinitis pigmen-
tosa. However, deferoxamine is a cumbersome iron chelator
requiring subcutaneous or intravenous administration due to
its poor absorption by the GI system. In addition, deferoxam-
ine has serious systemic side effects including pulmonary tox-
icity, bony changes, growth failure, and promotion of Yersinia
enterocolitica infections (De Virgiliis et al., 1988; Brill et al.,
1991; Tenenbein et al., 1992). Deferoxamine can also cause
retinotoxicity. Haimovici et al. describe macular and periph-
eral pigmentary changes, as well as reduction in retinal function
as indicated by reduction in ERG amplitude and electroocu-
logram light-peak to dark-trough ratios (Haimovici et al.,
2002).
In contrast, deferiprone can be administered orally with
fewer systemic side effects which can be prevented by careful
monitoring. Oral deferiprone was found to be effective in decreas-
ing retinal iron levels and oxidative stress in mice with age-
dependent iron accumulation from combined Cp and Heph
deficiency (Hadziahmetovic et al., 2011b). Unlike deferoxam-
ine, deferiprone was not found to be toxic to the mouse retina.
The iron chelator salicylaldehyde isonicotinoyl hydrazone was
also found to reduce levels of reactive oxygen species and pre-
vent RPE cell death in human RPE cell lines with exposure to
oxidative stress (Kurz et al., 2009; Lukinova et al., 2009). In
the experiments conducted by Lukinova et al., the RPE cells
treated with SIH were also resistant to oxidative stress induced
by staurosporine, anti-Fas, and exposure to A2E plus blue light
(Lukinova et al., 2009). We also found that deferiprone can rescue
light-damage-induced photoreceptor death in which iron dys-
regulation is not the primary cause of the degeneration (Song
et al., 2012). Iron chelators, such as deferiprone, which have a
lower affinity for iron than deferoxamine, may have less poten-
tial to cause side effects by removing iron from proteins that
require an iron cofactor. Taken together, these results indicate
that iron chelation could protect the retina against a broad range
of insults. This has promising implications for the treatment of
retinal diseases.
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